Company Overview

Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapy and targeted oncology treatments and creating accessible, effective and potentially more affordable options for patients everywhere.

We are dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing and co-development opportunities that align with our areas of expertise, offering better patient outcomes and delivering significant value to the future of healthcare.

In addition to a research pipeline including several investigational medicines, Checkpoint Therapeutics has received U.S. Food and Drug Administration (FDA) approval for UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. For more information, visit www.unloxcyt.com.

Latest News

View all news

Stock Information

Latest Financial Results

Q3 2024

Quarter Ended September 30, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Report Links

IR Contacts

Company

Checkpoint Therapeutics, Inc.
95 Sawyer Road
Suite 110
Waltham, MA 02453
T: 781-652-4500
F: 646-619-4950
info@checkpointtx.com

Investor Relations

LifeSci Advisors, LLC
Ashley R. Robinson
Managing Director
T: 617-430-7577
arr@lifesciadvisors.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
info@vstocktransfer.com
https://www.vstocktransfer.com